The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
lutetium Lu 177-DOTA-octreotate
A radioconjugate consisting of the somatostatin analog octreotate labeled with lutetium Lu 177 with receptor ligand, beta-emitting radioisotope, and potential antineoplastic activities. Lutetium Lu 177-DOTA-octreotate binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Lutetium Lu 177-DOTA-octreotate is produced by substituting the natural amino acid Thr for the alcohol Thr(ol) at the C terminus of the somatostatin analog octreotide and chelating the octreotate to Lu 177 via dodecanetetraacetic acid (DOTA). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Abbreviations: | 177 Lu-DOTA-octreotate Lu-177-DOTA-octreotide | ||